Halozyme Therapeutics (HALO) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Halozyme Therapeutics (HALO) over the past year, gaining 75.7% versus a gain of 69.6%. Over five years, KRYS leads with a +571.8% price change compared with +192.4% for HALO. Halozyme Therapeutics is the larger company by market cap ($12.53 billion vs $9.82 billion), about 1.3 times the size.
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.4x vs 35.8x for Krystal Biotech). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 22.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | KRYS |
|---|---|---|
| Share price | $110.42 | $331.61 |
| Market cap | $12.53B | $9.82B |
| 1-day change | +0.53% | +1.32% |
| YTD return | +64.07% | +34.51% |
| 1-year return | +69.59% | +75.68% |
| 5-year return | +192.43% | +571.80% |
| P/E ratio (TTM) | 32.29 | 41.56 |
| Forward P/E | 10.39 | 35.78 |
| EPS (TTM) | $3.42 | $7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $389.13M |
| Revenue growth (YoY) | +37.55% | +33.94% |
| Net income (latest FY) | $316.89M | $204.83M |
| Gross margin | 83.62% | — |
| Operating margin | 33.58% | 41.45% |
| Net margin | 22.69% | 52.64% |
| 52-week high | $116.85 | $382.54 |
| 52-week low | $61.23 | $179.19 |
| Distance from 52-week high | -5.50% | -13.31% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.84% | +18.24% |
| Average volume | 2.19M | 381.46K |
| Shares outstanding | 113.50M | 29.60M |
| Employees | 423 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Krystal Biotech trades at a higher earnings multiple (41.6x vs 32.3x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 22.7 cents for Halozyme Therapeutics.
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
HALO vs KRYS FAQ
Which is bigger, Halozyme Therapeutics or Krystal Biotech?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.53B compared with $9.82B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, HALO or KRYS?
KRYS returned +75.68% over the past 12 months, compared with +69.59% for HALO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HALO or KRYS?
HALO has the lower trailing P/E at 32.3, versus 41.6 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Halozyme Therapeutics and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.